Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer
Treatment with intra-arterial (IA) gemcitabine led to an improvement in overall survival (OS) compared with continued treatment with intravenous (IV) gemcitabine plus nab-paclitaxel (Abraxane) in patients with locally advanced pancreatic cancer following sequential treatment with IV gemcitabine, nab-paclitaxel, and radiotherapy, according to data from the first interim analysis of phase 3 TIGeR-PaC trial (NCT03257033).
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
RenovoRx today presented new positive data on progression-free survival (PFS) from the pivotal Phase III open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (LAPC). The interim data was featured as a late-breaking oral presentation at the 2023 ESMO World Congress on Gastrointestinal Cancer, and presented by Michael J. Pishvaian, M.D., Ph.D., Johns Hopkins Medicine and Principal Investigator (PI) of the TIGeR-PaC study.